When a procedure moves from the OR to the office, the buyer, the evidence, and the sales assets change. Here's how to re-test your MedTech beachhead.
When the Procedure Moves, Your Go-to-Market Must Move Too
When a procedure moves to a new site of care, the buyer in the room often changes with it. A go-to-market plan built around the old setting deserves a second look before it receives more budget.
It's the third account meeting of the quarter, and everything is going well until the practice administrator asks a question nobody prepared for.
Your sales lead has covered the clinical data, the physician champion and the timeline for committee review. The administrator nods, then asks: How much time does this add to a patient visit, and who on my staff needs to learn how to use it?
Your plan was built around a hospital buyer. But the procedure is now happening in an exam room, and the person making the decision isn't the person your team prepared for.
The deck still opens with operating room outcomes. The rep training still assumes a procurement committee. The pipeline report still uses the stages you defined last year.
Nobody necessarily made a mistake. The market moved, and the plan stayed where it was.
For MedTech companies, that gap can become an expensive commercial problem. Before investing further in a go-to-market strategy, it's worth checking whether the buyer, workflow and evidence requirements still match the market you're trying to reach.
Why This Is Happening Now
Procedures are moving beyond traditional operating room settings, creating new opportunities and new adoption challenges for MedTech companies.
PharmExec recently covered the shift of ear tube procedures from the operating room into the physician's office. The potential benefits include greater convenience and reduced exposure to general anaesthesia. However, acceptance among ear, nose and throat specialists has been gradual, highlighting an important distinction: a technology can be ready before the workflow and stakeholders are ready to adopt it.
Policy changes are reinforcing the broader shift towards outpatient care. CMS's 2026 payment rule expanded the list of procedures eligible for ambulatory surgery centres (ASCs) and began phasing out the inpatient-only list. We explored the commercial implications of this change in our earlier article, CMS Just Moved 573 Procedures Into ASC. Does Your Commercial Strategy Know That?.
The decision-making environment can change alongside the care setting. In an ASC, for example, a physician owner or a small administrative team may have a more direct role in purchasing decisions than a centralised hospital procurement committee.
For commercial leaders, the implication is straightforward: a change in where a procedure takes place can affect who buys the product, what they need to know and how your team reaches them.
The opportunity is not simply to sell the same product into another setting. It's to understand whether your commercial approach still fits the way care is delivered.
The Buyer in the Room Changes
A hospital purchase may involve a value analysis committee, supply chain, a department chief and finance leadership. Your messaging, champion strategy and sales-cycle assumptions were probably built around that group.
In a physician's office or an ASC, the decision-making group may be smaller, and individual responsibilities can look very different.
A physician owner may weigh the clinical case alongside the financial implications. A practice administrator may focus on scheduling, staffing and operational disruption. The staff who prepare the room and support the procedure become important influencers because they experience the workflow every day.
Each person brings a different set of priorities.
A hospital committee wants to know whether a product meets its evaluation criteria. A practice administrator wants to know whether it will fit into an already busy day. Clinical staff need to understand what changes in their routine and how much training is involved.
If your commercial team has prepared only for the first conversation, the second can stall adoption before the clinical value has had a chance to speak for itself.
The question isn't just who uses your product. It's who needs to say yes, what matters to them and what could prevent them from moving forward.
The Evidence That Matters Changes
Evidence that supports a hospital review may not answer the first question a new buyer asks.
Clinical outcomes remain important in every setting. But a smaller care setting may also need practical evidence about setup time, training requirements, patient throughput, staffing and reimbursement.
This is where commercial teams can get stuck. They have strong clinical data and assume the evidence is covered.
The data may be sound. The issue may be how it is presented, or whether an important operational question remains unanswered.
You may need a one-page explanation of how the procedure fits into the new setting. You may need feedback from a practice that has introduced the technology. Or you may need a clearer explanation of reimbursement in that specific care setting.
The key is to distinguish between evidence you already have and evidence you still need to develop.
Don't overstate what your data demonstrates. Instead, identify the questions buyers are asking, map those questions against your existing proof and make the gaps visible.
That gives your team a more useful starting point than simply adding another clinical slide to the deck.
The Sales Assets That Work Change
Every commercial asset carries assumptions about the person using it and the environment in which it will be used.
When the care setting changes, those assumptions deserve another look.
The deck and one-pager: Do they lead with the value that matters most to the new buyer, or the value that mattered to the old one?
The demo: Can it work in an exam room with limited space and a short window, or does it assume a fully equipped operating room?
Training and support: Is the training designed for a surgical team when the people learning the process are office staff managing a full patient schedule?
The territory model: Hospital accounts may be concentrated, while practices and surgery centres can be more dispersed. Does your coverage model reflect that difference?
The pipeline stages: If the buying process has changed, do your sales stages, conversion assumptions and forecasts still reflect how decisions are made?
These questions don't automatically mean that everything needs rebuilding.
The objective is to identify the assets and processes that no longer fit the buying environment, then prioritise the changes that will make the biggest difference to adoption.
Start with the materials a buyer encounters first. If those don't answer the right questions, the rest of your sales process has a harder job to do.
Your Beachhead Has an Address
Your beachhead is the initial market segment you intend to win. Choosing it involves assumptions about where the procedure happens, who makes the decision, what evidence matters and how you can reach the buyer.
Once a strategy is approved and the team starts executing, those assumptions can become easy to overlook.
A shift in site of care can change the size and attractiveness of your beachhead.
A segment you ruled out two years ago may now offer a more accessible route to adoption. A segment you have invested heavily in may take longer to reach than your original plan anticipated.
Neither outcome is inherently good or bad. Both are useful signals that your commercial strategy may need to be reassessed.
The risk is continuing to invest in a plan simply because it was right when you created it.
New hires, trade shows, campaigns and sales collateral all commit more resources to your chosen direction. If the underlying assumptions have changed, that investment can make the eventual correction more expensive.
Re-testing your beachhead isn't about abandoning your strategy. It's about making sure the next investment is supported by the market as it exists today.
A Quick Test for Your Team
Before committing more budget to your current go-to-market plan, put these questions to your commercial leaders.
Who signs off on a purchase of our product today, and has that person changed in the last year?
Where are our best-fit procedures performed now, and where do we expect them to be performed in two years?
Can our sales team name the first three questions a buyer in the new setting is likely to ask?
Does our strongest evidence answer those questions, or does it primarily address the concerns of a hospital committee?
Do our demo, training and support models work in a setting with different staffing, space and time constraints?
Do our pipeline stages and forecast assumptions match how this buyer actually makes a decision?
Pay attention to the answers that begin with "we think", "probably" or "we haven't checked recently".
If three or more answers rely on assumptions rather than current evidence, pause before committing further spend to the existing plan. The next step is to validate those assumptions with the people involved in the buying process.
How to Re-Test Before You Spend More
You don't need a lengthy strategic review to start. A focused process can help you identify where your commercial approach needs to change.
1. Map the workflow before and after.
Document who does what, where and for how long in the original setting and the new one. Identify what has changed, who takes on new responsibilities and where operational friction could emerge.
These differences often reveal the buyer questions your team hasn't answered yet.
2. Talk to people in the new setting.
Speak with physician owners, administrators and the staff who support the procedure. Ask what influences their decisions, what concerns them about adoption and what would make implementation easier.
Listen for the questions they ask first and the language they use to describe the problem.
3. Re-score your beachhead.
Reassess your target segment, buyer, evidence requirements and route to market against what you've learned. Check whether your original priorities still hold and whether another segment now deserves consideration.
4. Rebuild only the assets that need to change.
Start with the materials buyers see in the first meeting. Update your messaging, demonstrations and supporting evidence where there is a clear gap. Avoid rebuilding everything before you've established what is actually missing.
5. Decide where the next investment should go.
With the new assumptions tested, revisit your commercial priorities. Your next hire, campaign, event or sales initiative should support the market and buying process you're trying to win now.
The objective is not to make your go-to-market plan more complicated. It's to make it more relevant to the people who need to adopt your product.
Make Sure Your Go-to-Market Fits the Market
Your product's clinical value doesn't disappear when a procedure moves to a different setting. What changes is how that value needs to be demonstrated, who needs to understand it and what else they need to see before adopting it.
For MedTech commercial leaders, this is an opportunity to step back before the next round of spending and test whether the strategy still fits the reality of care delivery.
When the procedure moves, re-test your beachhead against the new workflow before investing further in the plan you built for the old one.
If a shift in site of care is affecting your market and you'd value a senior second opinion on whether your go-to-market still fits the buyer, get in touch with Tribe Consulting to discuss your commercial strategy.
